AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 44.35 USD 2.42% Market Closed
Market Cap: 1.2B USD

AnaptysBio Inc
Total Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

AnaptysBio Inc
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
Total Assets
$353.1m
CAGR 3-Years
-17%
CAGR 5-Years
-2%
CAGR 10-Years
19%
Abbvie Inc
NYSE:ABBV
Total Assets
$133.9B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Total Assets
$58.5B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Amgen Inc
NASDAQ:AMGN
Total Assets
$90.1B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Assets
$24.9B
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Assets
$40.2B
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
23%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
48.62 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's Total Assets?
Total Assets
353.1m USD

Based on the financial report for Sep 30, 2025, AnaptysBio Inc's Total Assets amounts to 353.1m USD.

What is AnaptysBio Inc's Total Assets growth rate?
Total Assets CAGR 10Y
19%

Over the last year, the Total Assets growth was -28%. The average annual Total Assets growth rates for AnaptysBio Inc have been -17% over the past three years , -2% over the past five years , and 19% over the past ten years .

Back to Top